Team Triple Step Our Medical Advisory Board
Melinda Telli, M.D.
Dr. Melinda Telli is a medical oncologist at Stanford, devoted to clinical investigation in breast cancer particularly in the early disease setting. Dr. Telli received her undergraduate degree from University of Pennsylvania Magna Cum Laude (1996) and medical degree from George Washington University With Distinction (2002). She completed internship and residency in internal medicine at Stanford University (2002-2005), and then stayed at Stanford to pursue fellowship training in medical oncology (2005-2008). She is currently an Assistant Professor of Medicine in the Division of Medical Oncology at Stanford with a clinical and research focus on breast cancer.
Dr. Telli's primary research interest is the development of novel therapeutic strategies for the treatment of early stage triple-negative and BRCA mutation-associated breast cancer and she is the Study Chair for two Eastern Cooperative Oncology Group trials that are the first to investigate the PARP inhibitor iniparib (BSI-201) in an early stage patient population. She also has an interest in the prevention of treatment-related cardiac injury in breast cancer patients, and cardiotoxicity of novel anti-cancer agents.